Freestone Capital Holdings LLC Has $2.54 Million Holdings in Pfizer Inc. $PFE

Freestone Capital Holdings LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 20.7% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 104,855 shares of the biopharmaceutical company’s stock after selling 27,332 shares during the period. Freestone Capital Holdings LLC’s holdings in Pfizer were worth $2,542,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the 1st quarter valued at $27,000. Curio Wealth LLC lifted its holdings in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares in the last quarter. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the first quarter valued at about $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer in the second quarter valued at about $29,000. Finally, WPG Advisers LLC acquired a new position in shares of Pfizer in the first quarter valued at about $35,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.2%

NYSE PFE opened at $24.69 on Tuesday. The business has a fifty day moving average price of $24.76 and a two-hundred day moving average price of $24.31. The stock has a market capitalization of $140.40 billion, a PE ratio of 13.14, a PEG ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $28.14. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the company posted $0.60 EPS. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s payout ratio is presently 91.49%.

Analyst Ratings Changes

PFE has been the subject of a number of recent research reports. Bank of America boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley reduced their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.24.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.